This is a phase 1b, open label, non-randomized, sequential dose-escalation, multicenter trial in adult patients with chronic cold urticaria.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
5
100 mg capsules for oral administration
Charité - Universitätsmedizin Berlin Institute of Allergology
Berlin, Germany
Centre for Human Drug Research
Leiden, Netherlands
Safety as assessed by the incidence and severity of adverse events
Safety evaluations will include analyses of adverse events by treatment group
Time frame: From Day 1 through Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.